Genesis Therapeutics Stock

Genesis Therapeutics is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Genesis Therapeutics stock. Depending on Genesis Therapeutics’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Genesis Therapeutics stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.

Collective Liquidity can provide liquidity to shareholders of Genesis Therapeutics stock in two ways. First, Genesis Therapeutics employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Genesis Therapeutics stock. Note that all transactions in Genesis Therapeutics shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.

Genesis Therapeutics stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Genesis Therapeutics stock. Typically, shares of private companies like Genesis Therapeutics are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.

On Aug 2023, Genesis Therapeutics is reported to have closed an equity financing in which the investors valued the company at $430M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Genesis Therapeutics shares outstanding assuming the conversion of all stock options, warrants, etc.

Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Genesis Therapeutics is not currently publicly traded, it does not have a ticker symbol.

Genesis Therapeutics has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Genesis Therapeutics is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Genesis Therapeutics shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.